


Drug pKa + Lipophilicity + GI-pH partition hypothesis [BRODIE]

↳ The process of drug absorption from the GIT & its distribution across all biological membranes.

↳ mol. wt > 100 → passive diffusion → Abs. govern. by

1. pKa of drug. (Dissociation constant).
2. lipid sol. of un-ionized drug K_{ow} .
3. pH at abs. site.

↳ Drugs (wk-acids/bases) → Ionization depend upon pH of bio fluids



↳ for Abs ↑

'Hypothesis' more permeation & Abs.
 GI in a simple lipidal barrier

Large fraction of un-ion. form + more lipophilicity of drug K_{ow} .

⇒ Drug pKa + GI pH

drug un-ionized form is a fⁿ of pKa of drug + pH of body fluids.

↳ Lower the pKa of acidic drug → strong acid + more ionization.

higher the pKa of basic drug → st. base + more ionization.

Henderson-Hasselbalch Eq: → Relative amt. of ionized & un-ionized drug.

for wk. acids:

$$pH = pKa + \log \frac{[\text{Ionized drug}]}{[\text{un-ionized drug}]}$$

$$\% \text{ Drug ionized} = \frac{10^{(pH - pKa)}}{1 + 10^{(pH - pKa)}} \times 100$$


for wk. bases:

$$pH = pKa + \log \frac{[\text{un-ionized drug}]}{[\text{ionized drug}]}$$

∴ ionized = un-ionized.
 log(1) = 0.

$$\% \text{ Drug ionized} = \frac{10^{(pKa - pH)}}{1 + 10^{(pKa - pH)}} \times 100$$

$$pH = pKa$$



Shore - et al. Theoretical ratio (R)

wk. acids:

$$P_a = \frac{C_{GIT}}{C_{plasma}} = \frac{1 + 10^{(pH_{GIT} - pK_a)}}{1 + 10^{(pH_{plasma} - pK_a)}}$$

wk. bases:

$$P_b = \frac{C_{GIT}}{C_{plasma}} = \frac{1 + 10^{(pK_a - pH_{GIT})}}{1 + 10^{(pK_a - pH_{plasma})}}$$

⇒ pH range Stomach → (1-3) • Intestine → (5-8).

↪ Ionisation = Abs. of drugs:

for wk. acids:

1. very wk. acids ($pK_a > 8.0$) ↔ un-ionised at all pH = absorb along GIT. ↗ pH-independent Abs.

Ex phenytoin • phenobarbital • ethosuximide • barbiturates, hexobarbital.

2. mod. wk. acids ($pK_a 2.5 - 7.5$) ↔ un-ionised in stomach pH → ✓.

Ex: cloxacillin • Aspirin • Ibuprofen • phenylbutazone • NSAIDs. ↘ ionised at Int. pH → (X),
pH-dependent abs.

3. st. acids ($pK_a < 2.5$) ↔ ionised entire pH-range of GIT → (X).

Cromolyn sodium. → poorly absorbed.

for basic drugs:

1. very wk. bases ($pK_a < 5.0$): ↔ un-ionised at all pH → ✓.

Ex: caffeine, theophylline • diazepam
oxazepam, nitrazepam. pH-independent abs.

2. mod. wk. bases ($pK_a 5 - 11.0$) ↔ Ionised at stomach pH → (X).

morphine, codeine, Heroin • imipramine, amitriptyline • chloroquine un-ionised at Int. pH → ✓.

3. st. bases ($pK_a > 11.0$). ↔ Ionised entire pH range → (X).

Guanethidine • mecamylamine.

→ Total aq. solubility (S_T) = S_a (sol.) + S_b (sol.)
Cmen-g ionized drug + Cmen-g un-ionized drug

for acidic drugs

$$S_T = S_a [1 + 10^{(pH - pK_a)}]$$


Intrinsic solubility

S_a → Intrinsic solb. of wk. Acid.

basic drugs:

$$S_T = S_b [1 + 10^{(pK_a - pH)}]$$

pH-solubility curves:



for wk. acids:

- 1. if $pH > pK_a$, $S_T \gg S_a$ → ionization of drug ↑
- 2. $pH = pK_a$, $S_T = 2S_a$ → 50% of drug ionized.
- 3. $pH < pK_a$, $S_T \approx S_a$ → un-ionized form of drug → more.

for wk. base:

- 1. $pH > pK_a$, $S_T \approx S_b$ → un-ionized form.
- 2. $pH = pK_a$, $S_T = 2S_b$ → 50% of drug ionized.
- 3. $pH < pK_a$, $S_T \gg S_b$ → ionization of drug ↑

Lipophilicity & Drug Absorption

↳ for opt B.A → drug have opt. HLB.
 ↳ sufficient solubility in fluids at Abs. Site
 ↳ penetration of drug through bio-membrane.

drug pKa → ionised & unionised
 ↓ ⊗ Abs
 oil sol. ✓
 ✓
 K_{o/w} 1, less lipid soluble ⊗

↳ Lipid solubility measured.
 $\log P$ (P → drug K_{o/w})
 ↳ degree of distribution of drugs betⁿ lip. solvent (n-octanol) & aq. phase (H₂O/buffer)

ex. Octanol / pH 7.4 buffer → K_{o/w} 1-2 → ⊗ passive abs.

↳ Ionisable drug: not partition into aq. phase.

apparent part. coeff (D).


for acidic drugs: $\log D = \log P - \log [1 + 10^{(pH - pKa)}]$

basic drugs $\log D = \log P - \log [1 + 10^{(pKa - pH)}]$

Limitation of pH-partition hypothesis:

1. presence of virtual membrane pH.
2. Absorption of ionised drug.
3. Influence of GI S.A & residence time of drug.
4. presence of aq. unstirred diffusion layer.

1. presence of v.m. pH:



pH-absorption curve.
 for acids → stomach Abs ↑
 lower pH.

ex. salicylic acid

acidic → shift Right → higher pH.

basic → shift Left → lower pH.

reasons microclimate pH differs from luminal pH.

↳ drug ionisation & Abs.

2) Abs. of mixed drug:

mixed < non-mixed, Abs ↑
 ↓
 Low K_o/w = Abs ↓ (3-4) Abs ↑ ← non-ionic diffusion

But: drug c large lipophilic group. → Abs ↑ (passive diffusion, other means, active transport, ion-pair transport, convective flow)

Ex: morphinan deriv.


3) Influence of G.I S.A & res. time of drugs

acidic drugs → in stomach abs ↑ → acidic pH } True if
 basic drugs → in intestine abs ↑ → alk. pH. } Stomach & Int. S.A is same
 reach int. → poorly abs
 reach int → abs ↑

But practically both H^+/OH^- drugs → Abs ↑ in Intestine.
 ↓ reason.

Large S.A = Long res. time.

4) presence of aq. unstirred diffusion layer:



→ bulk of luminal fluid not contact c lipoidal membrane.
 → Thickness c barrier → RDS
 y drug K_o/w → ↑ penetration to lipid.
 RDS → pen. to aq. unstirred.
 Ex. fatty acids & bile acids.

opt HLB

Drug permeability & Abs:

→ drug abs. (M).

$$M = C_{app} \cdot A \cdot P_{eff} \cdot t_{res}$$

M → amt. of drug absorbed, P_{eff} → effective membrane permeability,

A → S.A. available for Abs, t_{res} → res. time of drug in GI lumen,

→ apparent luminal drug concn,

M ↑ → (A) → not changeable so, $P_{eff} \uparrow$ & C_{app} .

→ factors: determine drug passive transport.

- 1) Lipophilicity of drug ($\log P$),
- 2) polarity of drug (no. of H-bond acceptor & H-bond donor),
- 3) mol. size,

→ Rule of Five Lipinski

→ mol. wt ≤ 500 ; lipophilicity $\log P \leq 5$

no. of H-bond acceptors ≤ 10 ; no. of H-bond donors ≤ 5 .

$\log P \rightarrow 1-2$

Drug - stability:

→ destabilisation → during shelf. life (i) in GIT.

→ drug degradation into inactive form,

→ form complex with GIT components / fluids,

→ drug. exp. interactions.

Stereochemical nature of drug: Chiral drugs → 60%.

→ Racemic mixtures.

→ Optical isomers → differ in potency & physiological response & effect.

Enantiomers → diff in spatial configuration.

A.D.M.E 11.

→ protein binding → stereoselectivity.

carrier-mediated transport.